Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts: read them as interpretation, each grounded in the data and the entities it names.
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Boards are working through a dense stretch of governance events: Helen of Troy rejecting Empower Brands' $37 cash proposal, Oasis's nominee standing at Vail Resorts' Dec 14 meeting, and a BAM take-private proposal for BEEP under special committee review. Planned CEO successions (Davis succeeding Hogan at Align), board refreshes (Mineralys, Fractyl, Bausch + Lomb), SPAC extensions (Globa Terra) and wind-downs (Elme Communities) add to the picture. Universal proxy card rules have pushed activist campaigns toward negotiated settlements. AI is a smaller thread: employers are warned that staff running confidential data through consumer AI tools may breach trade-secret agreements, which is prompting rewrites of confidentiality and invention-assignment contracts.
CFOs across biotech, medtech, energy, mining, semiconductors and fintech/adtech are using Q3 2026 earnings to stress cash preservation, cost cuts and integration wrap-up. Examples include Fractyl's ~50% cut in cash burn, TriSalus's lower-burn growth plan, Infineon's falling idle costs, and NGS's final integration quarter. Capital moves are also under way: Atrium's $50M placement, a credit-facility redraw to repay convertibles, Eagle Ford and Lubes divestitures/spinoffs, and System1's planned NYSE delisting. Regulatory events (Durbin Amendment impact on Origin Bancorp, the FDA PDUFA date for ivonescimab, the Florida City Gas rate case, Alberta auto reform) set the 2027 backdrop. Little of this material concerns AI or fintech directly; the link is the Startpage monetization pressure at System1 and the Durbin effect on bank interchange.
Biotech fundamentals are advancing on several fronts: Vor Biopharma's TELIGAN Phase 3 win, Incyte's PDAC data, Scribe's in vivo CRISPR program with $174.2M cash, and AI-designed viruses treating a first patient at Radical Numerics. Meanwhile, a $1 trillion tech selloff, OpenAI cutting its funding target and $3.6B in Binance withdrawals show a risk-off turn in AI and crypto capital markets. Biotech is therefore pairing real clinical and AI-enabled progress with a tighter funding backdrop, so the winners are likely to be companies with cash runways and late-stage data. Eli Lilly's strong demand and BioArctic's royalty growth show where revenue is already flowing.
In early November 2026 the Nasdaq had its worst day since April 2025 and the Magnificent Seven lost over $1 trillion. Pressure came from a hotter-than-expected October CPI and Democratic plans to rein in Big Tech. Meanwhile, financial services firms (East West, FNF, Aventus, LY Corp, Canara HSBC Life) reported solid Q3 results with raised guidance, fee growth and deal activity, such as the Aventus-Nomura joint venture. J.P. Morgan's selective aerospace and defense calls and a run of CEO successions suggest investors are rotating from richly valued AI and tech names toward earnings-backed value and leadership continuity.
On Nov 5, 2026 the AI and data-center trade sold off hard. The PHLX Semiconductor Index had its worst session since March 2020, the S&P 500 had its worst day since the April 2025 tariff crash, and the Nasdaq entered correction. Nvidia leadership turmoil (reported CEO ouster plans and a spy scandal stalling export-curb tightening) and strategists downgrading US stocks and global tech to neutral added to the pressure. Company-level data stayed solid: Siltronic hit record 300mm shipments and narrowed 2026 guidance upward, and Lynx kept Micron and Sandisk at clear buy with 33% and 49% upside. Infineon's decision to stop disclosing backlog and a wave of consolidation (Winbond buying Infineon's NOR Flash and F-RAM business for USD 1.12B, Kalray/Bull) point to a cautious, restructuring phase. The Nov 6 and Nov 9 rebounds were only partial.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedAdvanced Energy Reports Third Quarter 2026 Results
“Advanced Energy Reports Third Quarter 2026 Results Revenue was $696 million, up 50% year-over-year and above the high end of guidance Semiconductor and Data Center Computing revenue reached record levels, growing 64% and 49% year-over-year, respectively GAAP gross margin was 41.5%; non-GAAP gross margin was 42.1% GAAP…”
5 Worst Dow Stocks To Buy According to Analysts
“5 Worst Dow Stocks To Buy According to Analysts Yahoo Finance reported on November 5 that the Dow Jones Industrial Average tumbled 3.4%, or more than 1,800 points, while the S&P 500 fell 4.4% and the Nasdaq Composite sank 5.5% into correction territory…”
Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth
“Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth Earnings Call Insights: Oceaneering International, Inc…”
Corporate America’s big job cuts in 2026 - What do we know so far?
“Corporate America’s big job cuts in 2026 - What do we know so far? Corporate workers in America have faced the brunt of job cuts since the start of the year…”
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
“Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expe…”
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
“Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen…”
Every fact is traceable to the document it came from: see how we source every claim.
Late-stage trial data and royalty income keep arriving in biotech, while a $1 trillion tech selloff and a cut to OpenAI's funding target signal tighter capital. Via News checked the Incyte balance sheet against SEC filings and weighed each company claim by its source.
Salesforce's $5.66 billion Braze deal and ServiceNow's agent-governance push show vendors consolidating around AI agents. A Norwest investor says AI shouldn't do finance calculations. Trimble's guidance and TEN Holdings' results show returns are uneven.
Nasdaq plans a 23-hour trading day, Cboe and Robinhood plan company-specific event contracts, and the CFTC is suing states while it weighs 24/7 derivatives. Robinhood's SEC-filed numbers show how large the bet is. The sources behind the surrounding claims are less reliable, and we flag that.
Akeso's ivonescimab beat AstraZeneca's durvalumab on overall survival in a Phase III biliary tract cancer trial. Summit Therapeutics, which develops the drug, has no revenue and lost $1.08 billion in FY2025, per SEC filings. We checked each figure against its source.
Exchanges are planning a 23-hour trading day while regulators weigh 24/7 derivatives. Robinhood's checked SEC figures and its Q3 2026 results show retail demand shifting from crypto to event contracts. Every number here comes from SEC filings or named sources, and we flag where sources differ.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3 while crypto fell 55%, and Nasdaq and the CFTC are weighing near-24-hour markets. We checked each figure against SEC filings and graded the sources. Several key claims come from sources with mixed track records.
Checked SEC filings show Micron's capital spending nearly doubled in a year and its cash reached $25.0 billion. Record results at smaller suppliers add to the picture. We also flag where the sources disagree and which have a weak track record.
Funding is concentrating on proving who an AI agent is and who it acts for, while incumbents buy and brokers launch new products. SEC-filed figures show Robinhood's revenue rose from $1.865 billion to $4.473 billion in two years. One investor warns AI should not do finance maths.
In its latest quarter Robinhood reported event-contract revenue of $173M, up more than sixfold, while crypto revenue fell 55%. Nasdaq, Cboe and the CFTC are all pushing toward longer trading hours. Every figure here is traced to SEC filings or named documents, and we flag where sources are weaker.
Vor Bio reported two-year Phase 3 kidney results, Incyte's SEC-filed profit rose from $32.6 million to $1.29 billion in a year, and BioArctic's Leqembi royalty grew. Much of the early-stage news rests on company statements. We separate checked figures from claims.
Third-quarter reports split into two stories: a chip-equipment maker guiding to $8.6 billion of quarterly revenue on AI spending, and chemical and rail CFOs trimming costs against fuel and energy. We checked Dow's figures against SEC filings and flag where the evidence is thin.
Third-quarter calls from Lam Research, Dow and Union Pacific show two economies. AI-linked chip demand is outrunning supply, while chemicals and rail protect profit through cost cuts. Every figure is traced to a named speaker, an SEC filing or a source document.
Web Summit Lisbon's edition returns from 9 to 12 November, and the organisers' featured speakers page has a detail still rare at tech conferences: two of the "speakers" are robots.
Dow says its cost-cutting is ahead of schedule while its latest full-year results show the hole it is climbing out of. Union Pacific posted record profit and wants a merger. Both claims come from earnings calls, and the source's measured accuracy is 60%, so we separate what SEC filings confirm from what executives said.
Q3 2026 earnings calls show finance chiefs relying on cost cuts and cash cushions while energy costs stay high. Dow targets $1.3 billion of net benefits and Union Pacific's fuel price rose 64%. The figures come from earnings-call transcripts and SEC-checked filings; we flag where reporting is less certain.
Robinhood's checked SEC figures show revenue up about 2.4 times in two years and a swing from loss to profit. Now it is the first retail broker to offer Cboe's company-performance contracts, while startups raise money to prove AI agents can be trusted. Some of the evidence is thin, and we say where.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
The FDA approved a twelfth Tecentriq use, and a decision on Summit's ivonescimab is due Nov 14. Summit's SEC-filed accounts show losses and cash burn rising sharply. AstraZeneca's AI vision is, by its own telling, a forecast and not yet a result.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
Cancer drug makers are betting on newer treatment types, and regulators have started to approve some. Summit Therapeutics' filings show how costly that bet is: a $1.08 billion net loss in 2025 with zero revenue. The FDA rules on its lead drug on Nov. 14. The AI claims behind the story are forecasts, not results.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
Every fact here is structured and source-traced, so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.